Roflumilast - An oral anti-inflammatory treatment for chronic obstructive pulmonary disease: A randomised controlled trial

Lancet

Volumn 366, Issue 9485, 2005, Pages 563-571

  Rabe, Klaus F ^a   Bateman, Eric D ^b   O'Donnell, Denis ^c   Witte, Stephan ^d   Bredenbröker, Dirk ^d   Bethke, Thomas D ^d  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c KINGSTON GENERAL HOSPITAL   (Canada)

^d ALTANA PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; PHOSPHODIESTERASE IV INHIBITOR; PLACEBO; ROFLUMILAST;

ADULT; AGED; ARTICLE; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OUTPATIENT DEPARTMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

EID: 23744451716     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)67100-0     Document Type: Article

References (33)

1. RJ Halbert, S Isonaka, D George, A Iqbal Interpreting COPD prevalence estimates: what is the true burden of disease? Chest 123 2003 1684 1692
2. CJ Murray, AD Lopez Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study Lancet 349 1997 1498 1504
3. RA Pauwels, KF Rabe Burden and clinical features of chronic obstructive pulmonary disease (COPD) Lancet 364 2004 613 620
4. Global Initiative for Chronic Obstructive Lung Disease Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Based on an April 1998 NHLBI/WHO 2004 National Heart, Lung and Blood Institute Bethesda, Maryland
5. PM Calverley, P Walker Chronic obstructive pulmonary disease Lancet 362 2003 1053 1061
6. G Viegi, A Scognamiglio, S Baldacci, F Pistelli, L Carrozzi Epidemiology of chronic obstructive pulmonary disease (COPD) Respiration 68 2001 4 19
7. JC Hogg Pathophysiology of airflow limitation in chronic obstructive pulmonary disease Lancet 364 2004 709 721
8. PJ Barnes, SD Shapiro, RA Pauwels Chronic obstructive pulmonary disease: molecular and cellular mechanisms Eur Respir J 22 2003 672 688
9. MS Barnette Phosphodiesterase 4 (PDE4) inhibitors in asthma and chronic obstructive pulmonary disease (COPD) Prog Drug Res 53 1999 193 229
10. CH Compton, J Gubb, R Nieman Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study Lancet 358 2001 265 270
11. DS Bundschuh, M Eltze, J Barsig, L Wollin, A Hatzelmann, R Beume In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor J Pharmacol Exp Ther 297 2001 280 290
12. A Hatzelmann, C Schudt Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro J Pharmacol Exp Ther 297 2001 267 279
13. BJ Lipworth Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease Lancet 365 2005 167 175
14. Global Initiative for Chronic Obstructive Lung Disease Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report 2001 National Heart, Lung and Blood Institute Bethesda, Maryland
15. American Thoracic Society Standardization of spirometry, 1994 update Am J Respir Crit Care Med 152 1995 1107 1136
16. PH Quanjer, GJ Tammeling, JE Cotes, OF Pedersen, R Peslin, JC Yernault Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society Eur Respir J Suppl 16 1993 5 40
17. PW Jones, FH Quirk, CM Baveystock, P Littlejohns A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire Am Rev Respir Dis 145 1992 1321 1327
18. W Szafranski, A Cukier, A Ramirez Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease Eur Respir J 21 2003 74 81
19. P Calverley, R Pauwels, J Vestbo Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial Lancet 361 2003 449 456
20. EF Hansen, J Vestbo, K Phanareth, A Kok-Jensen, A Dirksen Peak flow as predictor of overall mortality in asthma and chronic obstructive pulmonary disease Am J Respir Crit Care Med 163 2001 690 693
21. DC Grootendorst, SA Gauw, R Baan Does a single dose of the phosphodiesterase 4 inhibitor, cilomilast (15 mg), induce bronchodilation in patients with chronic obstructive pulmonary disease? Pulm Pharmacol Ther 16 2003 115 120
22. R Engelstätter, M Wingertzahn, C Schmid-Wirlitsch, D Bredenbröker, S Leichtl, W Wurst Roflumilast, an oral, once-daily phosphodiesterase 4 (PDE4) inhibitor, does not exhibit bronchodilatory activity Ann Allergy Asthma Immunol 94 2005 169
23. RK Kumar, C Herbert, PS Thomas Inhibition of inflammation and remodeling by roflumilast and dexamethasone in murine chronic asthma J Pharmacol Exp Ther 307 2003 349 355
24. ES Muise, IC Chute, D Claveau Comparison of inhibition of ovalbumin-induced bronchoconstriction in guinea pigs and in vitro inhibition of tumor necrosis factor-alpha formation with phosphodiesterase 4 (PDE4) selective inhibitors Biochem Pharmacol 63 2002 1527 1535
25. W Timmer, V Leclerc, G Birraux The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-α ex vivo J Clin Pharmacol 42 2002 297 303
26. Committee for Proprietary Medicinal Products (CPMP) Points to consider on clinical investigation of medicinal products in the chronic treatment of patients with chronic obstructive pulmonary disease (COPD); May 19, 1999. CPMP/EWP/562/98 1999 The European Agency for the Evaluation of Medicinal Products London, UK
27. PM Calverley, W Boonsawat, Z Cseke, N Zhong, S Peterson, H Olsson Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease Eur Respir J 22 2003 912 919
28. R Casaburi, DA Mahler, PW Jones A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease Eur Respir J 19 2002 217 224
29. JF Donohue, JA van Noord, ED Bateman A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol Chest 122 2002 47 55
30. PS Burge, PM Calverley, PW Jones, S Spencer, JA Anderson, TK Maslen Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial BMJ 320 2000 1297 1303
31. DE O'Donnell Breathlessness in patients with chronic airflow limitation: mechanisms and management Chest 106 1994 904 912
32. MP Swanney, RL Jensen, DA Crichton, LE Beckert, LA Cardno, RO Crapo FEV(06) is an acceptable surrogate for FVC in the spirometric diagnosis of airway obstruction and restriction Am J Respir Crit Care Med 162 2000 917 919
33. DE O'Donnell, M Lam, KA Webb Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease Am J Respir Crit Care Med 160 1999 542 549